

Date and Time: *Monday 10th & Tuesday 11th December 2012 (10.00 – 4.00pm)*

Minutes: to be confirmed

Guideline Development Group Meeting 3: Dyspepsia & GORD

Place: NICE Offices, 10 Spring Gardens, London SW1A 2BN

Present: Peter Barry (Chair) (PB)
Hugh Barr (HB)
John de Caestecker (JD)
Mark Follows (MF)
Alex Ford (AF)
Ann Harding (AH)
Janusz Jankowski (JJ)
Mimi McCord (MM)
Marco Novelli (MN)

In attendance:

NICE Staff:		
Emma Banks (EB)	Annette Mead (AM)	
Steven Barnes (SB)	Gabriel Rogers (GR)	
Jenny Craven (JC)	Rachel Ryle (RR)	
Katy Harrison (KH)	Toni Tan (TT)	
Emma McFarlane (EM)	Thomas Wilkinson (TW)	

Observers:

Alex Thompson		
---------------	--	--

Notes

Day 1

1. PB welcomed the group to the third meeting of this GDG. Declarations of interest were received and recorded. Minutes for the previous meeting were agreed.
2. JC presented an overview of how the literature searches for review question 8 were carried out, explaining the search strategies employed and databases used.

Notes

3. SB presented a summary of the evidence for review question 8 which asks should surveillance be used for patients with Barrett's to detect progression of cancer? The group then discussed all the information presented having noted the evidence was limited and of poor quality. Evidence statements were reviewed and agreed.
4. TW presented both the PenTAG and Bhatt & Pitt model. He explained each model was highly applicable in helping to answer review question 8. Having taken the group through all the data TW ensured the group agreed with the structure, parameters and any sub-analysis required.
5. AM provided an overview of the role of the Editor and explained how the guideline recommendations will be presented and the aim of each product.
6. Following the Editors presentation with included advice on the strength and wording of recommendations given the evidence the group drafted a number of recommendations for review question 8.
7. PB closed the meeting with a summary of the day.

Day 2

8. PB opened the meeting with a review of the previous day and discussed the plan for day 2.
9. Review protocols for questions 1 and 2 were revisited for SB to gain further clarifications from the GDG.
10. EM provided an update on the H.pylori questions - outlining progress on the evidence for 1st line treatments and asking for further clarification on the 2nd & 3rd line treatments in order to finalise the review protocol.
11. Review protocols for questions 1 and 4 were revisited for TW to gain further clarifications from the GDG.
12. PB closed the meeting and thanked everyone for attending.

Date and venue of the next meeting:

Next Meeting: 4th February at NICE office, 10 Spring Gardens, London, SW1A 2BU